aristolochic acid D : An aristolochic acid that is phenanthrene-1-carboxylic acid substituted by a methylenedioxy group at the 3,4 positions, by an hydroxy group at position 6, by a methoxy group at position 8, and by a nitro group at position 10. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 161218 |
| CHEMBL ID | 604748 |
| CHEBI ID | 194152 |
| Synonym |
|---|
| aristolochic acid-d |
| smr001397396 |
| aristolochic acid iva |
| MLS002473315 |
| 17413-38-6 |
| 4'-(trifluoromethyl)acetophenone-13c6 |
| FT-0662285 |
| aristolochic d |
| aristolochic acid-iva |
| CHEMBL604748 , |
| bdbm50306860 |
| CHEBI:194152 |
| 10-hydroxy-8-methoxy-6-nitrophenanthro[3,4-d][1,3]dioxole-5-carboxylic acid , |
| aristolochic acid d |
| 10-hydroxy-8-methoxy-6-nitro-2h-phenanthro[3,4-d][1,3]dioxole-5-carboxylic acid |
| 10-hydroxy-8-methoxy-6-nitronaphtho[2,1-g][1,3]benzodioxole-5-carboxylic acid |
| NCGC00247571-01 |
| ccris 2995 |
| HMS2270M20 |
| 10-hydroxy-8-methoxy-6-nitrophenanthro[3,4-d]-1,3-dioxole-5-carboxylic acid |
| AC-34512 |
| DTXSID40169766 |
| phenanthro[3,4-d]-1,3-dioxole-5-carboxylicacid,10-hydroxy-8-methoxy-6-nitro- |
| 1261395-75-8 |
| HY-N1465 |
| CS-0016912 |
| MS-25601 |
| phenanthro[3,4-d]-1,3-dioxole-5-carboxylic acid, 10-hydroxy-8-methoxy-6-nitro- |
| aristolochicacidd |
| AKOS040760135 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " However, the same AA-IVa dosage exhibited almost no nephrotoxicity and does not trigger RIF." | ( Differences in p38-STAT3-S100A11 signaling after the administration of aristolochic acid I and IVa may account for the disparity in their nephrotoxicity. Han, J; Li, C; Liang, A; Liu, C; Liu, S; Meng, J; Pan, C; Tang, X; Tian, J; Wang, D; Wang, F; Wang, L; Wang, Y; Xian, Z; Yi, Y; Zhang, Y; Zhao, Y, 2023) | 0.91 |
| Role | Description |
|---|---|
| carcinogenic agent | A role played by a chemical compound which is known to induce a process of carcinogenesis by corrupting normal cellular pathways, leading to the acquistion of tumoral capabilities. |
| metabolite | Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites. |
| nephrotoxin | A poison that interferes with the function of the kidneys. |
| toxin | Poisonous substance produced by a biological organism such as a microbe, animal or plant. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| C-nitro compound | A nitro compound having the nitro group (-NO2) attached to a carbon atom. |
| aristolochic acids | Organic heterotetracyclic compounds which are a group of nitro phenanthrene organic acids, naturally found in many kinds of plants, such as Aristolochia and Asarum, and widely cultivated in Asia.They are identified as a class 1 human carcinogen by the International Agency for Research on Cancer owing to their carcinogenicity and nephrotoxicity and can pose a significant hazard to food safety and human health. |
| aromatic ether | Any ether in which the oxygen is attached to at least one aryl substituent. |
| cyclic acetal | An acetal in the molecule of which the acetal carbon and one or both oxygen atoms thereon are members of a ring. |
| monocarboxylic acid | An oxoacid containing a single carboxy group. |
| organic heterotetracyclic compound | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| TDP1 protein | Homo sapiens (human) | Potency | 32.6427 | 0.0008 | 11.3822 | 44.6684 | AID686978 |
| importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 17.3484 | 5.8048 | 36.1306 | 65.1308 | AID540253; AID540263 |
| flap endonuclease 1 | Homo sapiens (human) | Potency | 56.2341 | 0.1337 | 25.4129 | 89.1251 | AID588795 |
| snurportin-1 | Homo sapiens (human) | Potency | 17.3484 | 5.8048 | 36.1306 | 65.1308 | AID540253; AID540263 |
| GTP-binding nuclear protein Ran isoform 1 | Homo sapiens (human) | Potency | 6.5131 | 5.8048 | 16.9962 | 25.9290 | AID540253 |
| geminin | Homo sapiens (human) | Potency | 0.7806 | 0.0046 | 11.3741 | 33.4983 | AID624296; AID624297 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Cyclin-dependent kinase 2 | Homo sapiens (human) | IC50 (µMol) | 25.0000 | 0.0004 | 1.0444 | 10.0000 | AID457604 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| histone kinase activity | Cyclin-dependent kinase 2 | Homo sapiens (human) |
| magnesium ion binding | Cyclin-dependent kinase 2 | Homo sapiens (human) |
| protein serine/threonine kinase activity | Cyclin-dependent kinase 2 | Homo sapiens (human) |
| cyclin-dependent protein serine/threonine kinase activity | Cyclin-dependent kinase 2 | Homo sapiens (human) |
| protein binding | Cyclin-dependent kinase 2 | Homo sapiens (human) |
| ATP binding | Cyclin-dependent kinase 2 | Homo sapiens (human) |
| protein domain specific binding | Cyclin-dependent kinase 2 | Homo sapiens (human) |
| cyclin binding | Cyclin-dependent kinase 2 | Homo sapiens (human) |
| cyclin-dependent protein kinase activity | Cyclin-dependent kinase 2 | Homo sapiens (human) |
| protein serine kinase activity | Cyclin-dependent kinase 2 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID457612 | Inhibition of CDK2 at 50 uM | 2010 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 20, Issue:4 | Semi-synthetic aristolactams--inhibitors of CDK2 enzyme. |
| AID457604 | Inhibition of CDK2 | 2010 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 20, Issue:4 | Semi-synthetic aristolactams--inhibitors of CDK2 enzyme. |
| AID578749 | Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced elastase release after 5 mins | 2011 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 21, Issue:6 | A novel alkaloid, aristopyridinone A and anti-inflammatory phenanthrenes isolated from Aristolochia manshuriensis. |
| AID578748 | Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced superoxide anion generation after 5 mins | 2011 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 21, Issue:6 | A novel alkaloid, aristopyridinone A and anti-inflammatory phenanthrenes isolated from Aristolochia manshuriensis. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 5 (50.00) | 24.3611 |
| 2020's | 4 (40.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||